Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jul 04, 2024 10:58am

95 Views

Post# 36118064

RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

Juky 04, 2024 - Roche/Genentech's anti-TIGIT immune checkpoint inhibitor program continues to fail, most recently in Skyscraper - 06 in NSCLC and Roche's anti-TIGIT failures further bolster's ONCY's de-risked, late-stage, near- term accretive acquisition value for pelareorep biologics drug platform therapy for use in multiple cancers.

"The first half of 2024 shows how the industry has learned to execute accretive deals ... ” the recent PwC report’s authors concluded.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China